HomeAwards Y.U.O. Podium Selections

December Meeting Y.U.O. Podium Selections

These abstracts are selected by the Young Urologic Oncologists Committee prior to the Winter Annual Meetings. The Committee selects the three* best abstracts submitted to be presented at the meeting by a resident or fellow. The awardees present their abstracts during the scientific program at the meeting.

*Four awardees were selected for the 15th Annual Meeting (2014)


    2016

    Brandon Manley, MD
    Characterizing Recurrent and Lethal Small Renal Masses in Clear Cell Renal Cell Carcinoma Using Recurrent Somatic Mutations

    2016

    Peter Chang, MD, MPH
    Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The Prost-QA/RP2 Consortium

    2016

    Simpa S. Salami, MD, MPH
    Prevalence and Prognostic Significance of Circulating Tumor Cells (CTC) in Clinically Localized Prostate Cancer

    2015

    Roland Seiler, MD
    Prediction of Lymph Node Metastases in Bladder Cancer Using Gene Expression Signatures of Primary Tumors

    2015

    Kelvin Moses, MD, PhD
    Patterns of PSA Screening Among Low Income African-American and Caucasian Men: Data from the Southern Community Cohort Study

    2015

    Richard Matulewicz, MD, MS
    Is Poor Adherence to Guidelines Further Evidence of the Need for Centralization of Penile Cancer Care?

    2014

    Arnold Chin, MD, PhD
    Role of RIP2 in Development of Tumor-Infiltrating MDSCS and Bladder Cancer Metastasis

    2014

    Ahmed Haddad, MD
    Preoperative Multivariable Prognostic Models for Prediction of Survival and Major Complications Following Surgical Resection of Renal Cell Carcinoma with Suprahepatic Caval Tumor Thrombus

    2014

    Timothy Daskivich, MD, MSHPM
    An Age-Adjusted Comorbidity Index for Prediction of Long-Term, Other-Cause Mortality in Men with Prostate Cancer

    2014

    Nicholas Cost, MD
    Referral Patterns in Testicular Cancer: Do They Impact Oncologic Outcomes?

    2013

    Florian Schroeck, MD
    The Impact of Technology Diffusion on Treatment for Prostate Cancer

    2013

    M. Minhaj Siddiqui, MD
    Utilization of a Prostate MRI Nomogram for Prediction of Biopsy Gleason Score

    2013

    John Sullivan, MD
    A Single Center Validation Analysis of Prostate Cancer Risk Loci from Published GWAs: Association with PSA Levels, Prostate Cancer Progression and Mortality

    2012

    Florian Schroeck, MD
    Large Regional Variation in Quality of Prostate Cancer Care Highlights Opportunity for Quality Improvement

    2012

    Adam Feldman, MD
    To Biopsy or Not to Biopsy: Results of 1000 Renal Mass Biopsies at a Single Institution

    2012

    Jeffrey Bassett, MD
    Introduction of a Tobacco-Screening Initiative for Those with or at Risk for Bladder Cancer: The Case of a High Volume Urology Clinic

    2011

    Uri Lindner, MD
    MR-Guided Laser Focal Therapy for Low - Intermediate Risk Localized Prostate Cancer

    2011

    Brian Schuch, MD
    Adrenal Nodular Hyperplasia as Part of the Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC) Phenotype

    2011

    Kenneth Nepple, MD
    Hospital Readmission After Radical Cystectomy for Bladder Cancer: Results of a Population-Based Analysis from the California State Inpatient Database

    2010

    Jose Karam, MD
    Development and Characterization of Tumor Models from Patients with Renal Cell Carcinoma

    2010

    Amit Gupta, MD
    Radical Cystectomy and Urinary Diversion is Associated with a Greater Risk of Fractures in Patients with Bladder Cancer

    2010

    David Margel, MD
    Oral Contraceptive Use is Associated with Prostate Cancer: An Ecologic Study

    2009

    Daniel A. Barocas, MD
    The Association Between Oxidative Stress and Prostate Cancer Risk in Men Undergoing Prostate Biopsy

    2009

    Shahrokh Shariat, MD
    HER2 Expression Status Provides Independent Prognostic Information in Patients with Urothelial Carcinoma of the Bladder

    2009

    Thomas Sanford, MD
    Molecular Sub-Classification of Renal Epithelial Neoplasms

    2008

    Jose Karam, MD
    Upregulation of TRAG3 (Taxol Resistance Associated Gene 3) is Associated with Advanced Bladder Cancer (BCA)

    2008

    Kiranpreet Khuran, MD
    Comparison of Primary and Metastatic to Lymph Node Cell Lines from the Same Patients

    2008

    Timothy A. Masterson, MD
    Clinical Outcomes in Clinical Stage III NSGCT Patients who Achieve a Complete Radiographic Response to Chemotherapy at the Site of Extra-Retroperitoneal Disease

    2007

    Brett Carver, MD
    Aberrant ERG Expression is a Critical and Causal Event in Prostate Tumorigenesis

    2007

    John Davis, MD
    Training Multiple Urologic Oncology Fellows in Robotic-Assisted Laparoscopic Prostatectomy

    2007

    Boris Hadaschik, MD
    Intravesical Therapy of High Grade Bladder Cancer with HTI-286

    2006

    Surena Matin, MD
    The Natural History of Residual and Recurrent Disease Following Renal Ablative Therapy: A Multi-Institutional Study

    2006

    Jim Hu, MD, MPH
    Perioperative Quality Care Indicators of Retropubic, Laparoscopic, and Robotic Prostatectomy: Results from a National, Multi-Center, Prospective Cohort

    2006

    Robert Nam, MD, MSc
    Genome-Wide Association Study for Prostate Cancer Using the Affymetrix 10k Genechip and Evaluation of Susceptibility Genes for Prostate Cancer in a Clinical Setting